Paclitaxel (Taxol) for adjuvant and neoadjuvant treatment of breast cancer
HAYES, Inc.
Record ID 32008000032
English
Authors' objectives:
Paclitaxel (Taxol) is a chemotherapeutic drug that is administered, alone or in combination with other agents, for treatment of primary breast cancer. Its purpose in the treatment of primary breast cancer is to kill additional cancer cells following surgery (adjuvant treatment) or to shrink tumor size so that surgery is more feasible (neoadjuvant treatment). The ultimate goal of chemotherapy is to prolong survival.
Authors' methods:
Review
Details
Project Status:
Completed
Year Published:
2007
URL for published report:
http://www.hayesinc.com/hayes/crd/?crd=7187
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Paclitaxel
- Breast Neoplasms
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
HAYES, Inc.
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.